Cargando…
Reply: Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2010
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2856007/ http://dx.doi.org/10.1038/sj.bjc.6605629 |
| _version_ | 1782180224860946432 |
|---|---|
| author | Novello, S Scagliotti, G V Rosell, R Socinski, M A Brahmer, J Atkins, J Pallares, C Burgess, R Tye, L Selaru, P Wang, E Chao, R Govindan, R |
| author_facet | Novello, S Scagliotti, G V Rosell, R Socinski, M A Brahmer, J Atkins, J Pallares, C Burgess, R Tye, L Selaru, P Wang, E Chao, R Govindan, R |
| author_sort | Novello, S |
| collection | PubMed |
| description | |
| format | Text |
| id | pubmed-2856007 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2010 |
| publisher | Nature Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-28560072011-04-13 Reply: Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors Novello, S Scagliotti, G V Rosell, R Socinski, M A Brahmer, J Atkins, J Pallares, C Burgess, R Tye, L Selaru, P Wang, E Chao, R Govindan, R Br J Cancer Letter to the Editor Nature Publishing Group 2010-04-13 2010-03-30 /pmc/articles/PMC2856007/ http://dx.doi.org/10.1038/sj.bjc.6605629 Text en Copyright © 2010 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
| spellingShingle | Letter to the Editor Novello, S Scagliotti, G V Rosell, R Socinski, M A Brahmer, J Atkins, J Pallares, C Burgess, R Tye, L Selaru, P Wang, E Chao, R Govindan, R Reply: Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors |
| title | Reply: Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors |
| title_full | Reply: Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors |
| title_fullStr | Reply: Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors |
| title_full_unstemmed | Reply: Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors |
| title_short | Reply: Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors |
| title_sort | reply: ongoing under-reporting of clinically relevant safety data in phase ii studies of tyrosine kinase inhibitors |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2856007/ http://dx.doi.org/10.1038/sj.bjc.6605629 |
| work_keys_str_mv | AT novellos replyongoingunderreportingofclinicallyrelevantsafetydatainphaseiistudiesoftyrosinekinaseinhibitors AT scagliottigv replyongoingunderreportingofclinicallyrelevantsafetydatainphaseiistudiesoftyrosinekinaseinhibitors AT rosellr replyongoingunderreportingofclinicallyrelevantsafetydatainphaseiistudiesoftyrosinekinaseinhibitors AT socinskima replyongoingunderreportingofclinicallyrelevantsafetydatainphaseiistudiesoftyrosinekinaseinhibitors AT brahmerj replyongoingunderreportingofclinicallyrelevantsafetydatainphaseiistudiesoftyrosinekinaseinhibitors AT atkinsj replyongoingunderreportingofclinicallyrelevantsafetydatainphaseiistudiesoftyrosinekinaseinhibitors AT pallaresc replyongoingunderreportingofclinicallyrelevantsafetydatainphaseiistudiesoftyrosinekinaseinhibitors AT burgessr replyongoingunderreportingofclinicallyrelevantsafetydatainphaseiistudiesoftyrosinekinaseinhibitors AT tyel replyongoingunderreportingofclinicallyrelevantsafetydatainphaseiistudiesoftyrosinekinaseinhibitors AT selarup replyongoingunderreportingofclinicallyrelevantsafetydatainphaseiistudiesoftyrosinekinaseinhibitors AT wange replyongoingunderreportingofclinicallyrelevantsafetydatainphaseiistudiesoftyrosinekinaseinhibitors AT chaor replyongoingunderreportingofclinicallyrelevantsafetydatainphaseiistudiesoftyrosinekinaseinhibitors AT govindanr replyongoingunderreportingofclinicallyrelevantsafetydatainphaseiistudiesoftyrosinekinaseinhibitors |